[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Aspire Biopharma Holdings Inc (ASBP)

Aspire Biopharma Holdings Inc (ASBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Income Statement for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)
  09-2022 06-2022 03-2022 12-2021 09-2021
Operating Expenses 255 298 109 0 15
Operating Income -255 -298 -109 N/A -15
Other Income 1,333 419 21 0 0
Pre-tax Income 1,077 121 -88 0 -15
Net Income Continuous 1,077 121 -88 N/A -15
Net Income $1,077 $121 $-88 $N/A $-15
EPS Basic Total Ops 36.04 0.00 -12.01 N/A 0.00
EPS Basic Continuous Ops 180.03 20.17 -14.68 N/A -2.94
EPS Diluted Total Ops 36.04 0.00 -12.01 N/A 0.00
EPS Diluted Continuous Ops 180.03 20.17 -14.68 N/A -2.94
EBITDA(a) $-255 $-298 $-109 $N/A $-15
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.